N-acyl phosphatidylethanolamine-specific phospholipase D

NAPE-PLD is an enzyme activity - a phospholipase, acting on phospholipids found in the cell membrane. It is not homology but the chemical outcome of its activity that classes it as phospholipase D. The enzymatic activity was discovered and characterized in a series of experiments culminating in the 2004 publication of a biochemical purification scheme from which peptide sequencing could be accomplished. Three corresponded to vimentin, an intermediate filament protein of 56 kDa believed to be a contaminant, and the other two matched the cDNA clone subsequently identified as NAPE-PLD. Once this clue had been obtained, the identification could be confirmed by a less onerous procedure: Overexpression of the putative NAPE-PLD cDNA in COS-7 cells yielded a strong NAPE-PLD enzymatic activity, whose characteristics were shown to be similar to those of the original heart extract. == Characteristics ==

The NAPEPLD cDNA sequence predicts 396 amino acid sequences in both mice and rats, which are 89% and 90% identical to that of humans. NAPE-PLD was found to have no homology to the known phospholipase D genes, but can be classed by homology to fall into the zinc metallohydrolase family of the beta-lactamase fold. In particular, the highly conserved motif HX(E/H)XD(C/R/S/H)X50–70HX15–30(C/S/D)X30–70H was observed, which is, in general, associated with zinc binding and hydrolysis reaction in this class of proteins, leading the authors to propose that activity should be correlated with zinc content. When recombinant NAPE-PLD was tested in COS cells in vitro it had similar activity toward several radiolabeled substrates: N-palmitoylphosphatidylethanolamine, N-arachidonoylphosphatidylethanolamine, N-oleoylphosphatidylethanolamine, and N-stearoylphosphatidylethanolamine all reacted with a Km between 2–4 micromolar and a Vmax between 73 and 101 nanomole per milligram per minute as calculated by Lineweaver–Burk plot. (These generate N-palmitoylethanolamine, anandamide, N-oleoylethanolamine, and N-stearoylethanolamine, respectively) The enzyme also reacted N-palmitoyl-lyso-phosphatidylethanolamine and N-arachidonoyl-lyso-phosphatidylethanolamine with similar Km but at one-third to one-fourth the Vmax. These activities are consistent with the observation that many tissues produce a range of N-acylethanolamines. However, NAPE-PLD had no ability to produce detectable phosphatidic acid from phosphatidylcholine or phosphatidylethanolamine as is catalyzed by other phospholipase D enzymes. It also lacks the transphosphatidylation activity of phospholipase D that allows the creation of phosphatidyl alcohols rather than phosphatidic acid in the presence of ethanol or butanol. == Pathway ==

This enzyme acts as the second step of a biochemical pathway initiated by the creation of N-acylphosphatidylethanolamine, by means of the transfer of an acyl group from the sn-1 position of glycerophospholipid onto the amino group of phosphatidylethanolamine. The N-acylethanolamines released by this enzyme become potential substrates for fatty acid amide hydrolase (FAAH), which hydrolyzes the free fatty acids from ethanolamine. Defects in this enzyme can cause NAPE-PLD products such as anandamide to build up to levels 15-fold higher than normally observed. == Structure ==

This membrane enzyme forms homodimers, partly separated by an internal ~9-Å-wide channel. The metallo beta-lactamase protein fold is adapted to associate with membrane phospholipids. A hydrophobic cavity provides an entry way for the substrate NAPE into the active site, where a binuclear zinc center catalyzes its hydrolysis. Bile acids bind with high affinity to selective pockets in this cavity, enhancing dimer assembly and enabling catalysis. NAPE-PLD facilitates crosstalk between bile acid signals and lipid amide signals. == Pharmacology ==

Thiazide and thiazide-like diuretics are among the most efficacious and used drugs for the treatment of hypertension, edema, and major cardiovascular outcomes. Despite more than six decades of clinical use, the mechanism of action by which these drugs cure hypertension after long-term use had remained mysterious. Recently, Garau Gianpiero and co-authors reported that the membrane enzyme NAPE-PLD is a renal and extrarenal target of hydrochlorothiazide, chlortalidone and indapamide, shedding light on their mechanism of action in the treatment of hypertension and cardiovascular diseases. As revealed by the crystal structures of NAPE-PLD in complex with hydrochlorothiazide and pyridoxal phosphate (PLP), thiazide molecules bind within the 9 Angostrom-wide internal channel of NAPE-PLD in a manner competitive with the cofactor PLP. In the presence of bile acids, the association of NAPE-PLD with membranes creates membrane pores as dynamic conductive pathways through which the charged PLP can diffuse through cell membranes and membranes of subcellular compartments (e.g., mitochondria and peroxisome). The fact that thiazide medications promote beneficial effects that involve directly a main protein of the endocannabinoid system, NAPE-PLD, reveals not only a novel target for cardiovascular disease, but a way to modulate efficaciously the endocannabinoid system in therapy. These results can be useful in the management of vascular risk factors,as well as associated leukoencephalopathy and demyelinating disease. ==References==